LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 53

Search options

  1. Book: Aerosolized drugs for the respiratory tract

    Rau, Joseph L.

    (Respiratory care clinics of North America ; 5,4)

    1999  

    Author's details Joseph L. Rau, guest ed
    Series title Respiratory care clinics of North America ; 5,4
    Collection
    Language English
    Size XVI S., S. 479 - 660 : Ill., graph. Darst.
    Edition Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT011162288
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Book: Respiratory care pharmacology

    Rau, Joseph L.

    1998  

    Author's details Joseph L. Rau
    Keywords Respiratory Therapy ; Bronchodilator Agents / pharmacology ; Bronchodilator Agents / administration & dosage ; Atemwege ; Pharmakotherapie
    Subject Arzneimitteltherapie ; Arzneitherapie ; Medikamentöse Therapie ; Luftwege ; Respirationstrakt ; Atmungssystem ; Atemsystem ; Apparatus respiratorius
    Language English
    Size XVII, 408 S. : Ill., graph. Darst.
    Edition 5. ed.
    Publisher Mosby
    Publishing place St. Louis u.a.
    Publishing country United States
    Document type Book
    Note Includes index
    HBZ-ID HT008489599
    ISBN 0-8151-2337-x ; 978-0-8151-2337-x8
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Book: Quick reference to aerosolized agents in respiratory care

    Rau, Joseph L.

    1994  

    Keywords Respiratory Therapy / handbooks ; Aerosols / therapeutic use / handbooks
    Language English
    Size 35 S.
    Publisher Mosby
    Publishing place St. Louis u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT006337354
    ISBN 0-8151-7078-5 ; 978-0-8151-7078-5
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Book: Respiratory care pharmacology

    Rau, Joseph L.

    1994  

    Author's details Joseph L. Rau
    Keywords Bronchodilator Agents / administration & dosage ; Bronchodilator Agents / pharmacology ; Respiratory Therapy
    Language English
    Size XVI, 492 S. : Ill., graph. Darst.
    Edition 4. ed.
    Publisher Mosby
    Publishing place St. Louis u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT006337371
    ISBN 0-8016-7184-1 ; 978-0-8016-7184-5
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  5. Book: Respiratory care pharmacology

    Rau, Joseph L.

    1989  

    Keywords Pharmacology ; Respiratory Therapy
    Size XV, 360 S. : Ill., graph. Darst.
    Edition 3. ed., 1. [Dr.]
    Publisher Year Book Medical Publ
    Publishing place Chicago u.a.
    Publishing country United States
    Document type Book
    Old title 2. Aufl. u.d.T Rau, Joseph L.: Respiratory therapy pharmacology
    HBZ-ID HT003361277
    ISBN 0-8151-7077-7 ; 978-0-8151-7077-8
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  6. Book: Respiratory therapy pharmacology

    Rau, Joseph L.

    1984  

    Keywords Respiratory Tract Diseases / drug therapy
    Size XIII, 316 S. : Ill., graph. Darst.
    Edition 2. ed.
    Publisher Year Book Med. Publ
    Publishing place Chicago
    Publishing country United States
    Document type Book
    HBZ-ID HT002822959
    ISBN 0-8151-7076-9 ; 978-0-8151-7076-1
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  7. Article ; Online: Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia.

    Conneely, Shannon E / McAtee, Casey L / Gupta, Rohit / Lubega, Joseph / Scheurer, Michael E / Rau, Rachel E

    Blood advances

    2022  Volume 5, Issue 23, Page(s) 4992–5001

    Abstract: Black and Hispanic children with acute myeloid leukemia (AML) have worse outcomes compared with White children. AML is a heterogeneous disease with numerous genetic subtypes in which these disparities have not been specifically investigated. In this ... ...

    Abstract Black and Hispanic children with acute myeloid leukemia (AML) have worse outcomes compared with White children. AML is a heterogeneous disease with numerous genetic subtypes in which these disparities have not been specifically investigated. In this study, we used the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database to examine the association of race-ethnicity with leukemia cytogenetics, clinical features, and survival outcomes within major cytogenetic subgroups of pediatric AML. Compared with White non-Hispanic patients, t(8;21) AML was more prevalent among Black (odds ratio [OR], 2.22; 95% confidence interval [CI], 1.28-3.74) and Hispanic patients (OR, 1.74; 95% CI, 1.05-2.83). The poor prognosis KMT2A rearrangement t(6;11)(q27;q23) was more prevalent among Black patients (OR, 6.12; 95% CI, 1.81-21.59). Among those with KMT2Ar AML, Black race was associated with inferior event-free survival (EFS) (hazard ratio [HR], 2.31; 95% CI, 1.41-3.79) and overall survival (OS) (HR, 2.54; 1.43-4.51). Hispanic patients with KMT2Ar AML also had inferior EFS (HR, 2.20; 95% CI, 1.27-3.80) and OS (HR, 2.07; 95% CI, 1.09-3.93). Similarly, among patients with t(8;21) or inv(16) AML (ie, core-binding factor [CBF] AML), Black patients had inferior outcomes (EFS HR, 1.93; 95% CI, 1.14-3.28 and OS HR, 3.24; 95% CI, 1.60-6.57). This disparity was not detected among patients receiving gemtuzumab ozogamicin (GO). In conclusion, racial-ethnic disparities in survival outcomes among young people with AML are prominent and vary across cytogenetic subclasses. Future studies should explore the socioeconomic and biologic determinants of these disparities.
    MeSH term(s) Adolescent ; Ethnicity ; Hispanic or Latino/genetics ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Phenotype ; Proportional Hazards Models
    Language English
    Publishing date 2022-07-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2021004735
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Gynecologic oncologists in surgery for placenta accreta spectrum: a survey for practice, experience, and interest.

    Matsuo, Koji / Vestal, Nicole L / Rau, Alesandra R / Sangara, Rauvynne N / Youssefzadeh, Ariane C / Bainvoll, Liat / Matsuzaki, Shinya / Roman, Lynda D / Ouzounian, Joseph G / Wright, Jason D

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2022  Volume 32, Issue 11, Page(s) 1433–1442

    Abstract: ... have experienced surgical blood loss >5 L and one-third (36.6%) have experienced cases with blood loss ... 10 L. About half (50.3%) of participants are interested in placenta accreta spectrum surgery ...

    Abstract Objective: Surgery for placenta accreta spectrum is associated with significant maternal morbidity and mortality. The role of gynecologic oncologists in the surgical management of placenta accreta spectrum is currently under investigation. This study examined the practices, experiences, and interests of gynecologic oncologists in placenta accreta spectrum surgeries.
    Methods: The intervention was an anonymous, cross-sectional, 20-question survey sent to 1084 members of the Society of Gynecologic Oncology in the USA.
    Results: A total of 184 gynecologic oncologists responded to the survey (response rate 17.0%). Most participating gynecologic oncologists have been practicing for >10 years after fellowship (53.2%), practice in urban-teaching hospitals (84.8%) with delivery volumes ≥3000/year (54.3%), and have a multidisciplinary approach (82.5%). Three-quarters (78.7%) feel that the rate of placenta accreta spectrum is increasing over time. One-third (35.5%) perform ≥6 hysterectomies for placenta accreta spectrum yearly. Less than half (45.5%) practice conservative management. Approximately half are involved from the beginning of the case (49.7%) and perform the surgery in the main operating room (59.4%). Almost three-quarters (71.6%) have experienced surgical blood loss >5 L and one-third (36.6%) have experienced cases with blood loss >10 L. About half (50.3%) of participants are interested in placenta accreta spectrum surgery for future practice. Gynecologic oncologists engaging in a multidisciplinary approach are more likely to practice in an urban-teaching hospital, have higher surgical volume, be involved from the beginning of the case, and be interested in placenta accreta spectrum surgery. Those >10 years post-training and in the Southern US region are more likely to practice conservative management or delayed hysterectomy.
    Conclusion: This society-based cross-sectional survey suggests that gynecologic oncologists are actively involved in the surgical management of placenta accreta spectrum in the USA. Nearly half of gynecologic oncologists who responded to the survey expressed interest in surgery for placenta accreta spectrum.
    MeSH term(s) Pregnancy ; Female ; Humans ; Placenta Accreta/surgery ; Cross-Sectional Studies ; Retrospective Studies ; Hysterectomy ; Oncologists
    Language English
    Publishing date 2022-11-07
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2022-003830
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Open-channel structure of a pentameric ligand-gated ion channel reveals a mechanism of leaflet-specific phospholipid modulation.

    Petroff, John T / Dietzen, Noah M / Santiago-McRae, Ezry / Deng, Brett / Washington, Maya S / Chen, Lawrence J / Trent Moreland, K / Deng, Zengqin / Rau, Michael / Fitzpatrick, James A J / Yuan, Peng / Joseph, Thomas T / Hénin, Jérôme / Brannigan, Grace / Cheng, Wayland W L

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 7017

    Abstract: Pentameric ligand-gated ion channels (pLGICs) mediate synaptic transmission and are sensitive to their lipid environment. The mechanism of phospholipid modulation of any pLGIC is not well understood. We demonstrate that the model pLGIC, ELIC (Erwinia ... ...

    Abstract Pentameric ligand-gated ion channels (pLGICs) mediate synaptic transmission and are sensitive to their lipid environment. The mechanism of phospholipid modulation of any pLGIC is not well understood. We demonstrate that the model pLGIC, ELIC (Erwinia ligand-gated ion channel), is positively modulated by the anionic phospholipid, phosphatidylglycerol, from the outer leaflet of the membrane. To explore the mechanism of phosphatidylglycerol modulation, we determine a structure of ELIC in an open-channel conformation. The structure shows a bound phospholipid in an outer leaflet site, and structural changes in the phospholipid binding site unique to the open-channel. In combination with streamlined alchemical free energy perturbation calculations and functional measurements in asymmetric liposomes, the data support a mechanism by which an anionic phospholipid stabilizes the activated, open-channel state of a pLGIC by specific, state-dependent binding to this site.
    MeSH term(s) Ligand-Gated Ion Channels/chemistry ; Ligand-Gated Ion Channels/metabolism ; Phospholipids ; Binding Sites ; Phosphatidylglycerols ; Liposomes
    Chemical Substances Ligand-Gated Ion Channels ; Phospholipids ; Phosphatidylglycerols ; Liposomes
    Language English
    Publishing date 2022-11-17
    Publishing country England
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, N.I.H., Extramural
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-34813-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Practical problems with aerosol therapy in COPD.

    Rau, Joseph L

    Respiratory care

    2006  Volume 51, Issue 2, Page(s) 158–172

    Abstract: Inhaled aerosol drugs commonly used by patients with chronic obstructive pulmonary disease include short-acting and long-acting bronchodilators, as well as corticosteroids. These agents are available in a variety of inhaler devices, which include metered- ...

    Abstract Inhaled aerosol drugs commonly used by patients with chronic obstructive pulmonary disease include short-acting and long-acting bronchodilators, as well as corticosteroids. These agents are available in a variety of inhaler devices, which include metered-dose inhalers (MDI), breath-actuated MDIs, nebulizers, and, currently, 5 different models of dry powder inhaler (DPI). There is evidence to suggest that multiple inhaler types cause confusion among patients and increase errors in patient use. Problems with MDIs include failure to coordinate inhalation with actuation of the MDI, inadequate breath-hold, and inappropriately fast inspiratory flow. Lack of a dose counter makes determining the number of remaining doses in an MDI problematic. Patient misuse of MDIs is compounded by lack of knowledge of correct use among health-care professionals. Several factors often seen with elderly patients have been identified as predictive of incorrect use of MDIs. These include mental-state scores, hand strength, and ideomotor dyspraxia. Holding chambers and spacers are partially intended to reduce the need for inhalation-actuation coordination with MDI use. However, such add-on devices can be subject to incorrect assembly. Possible delays between MDI actuation and inhalation, rapid inspiration, chamber electrostatic charge, and firing multiple puffs into the chamber can all reduce the availability of inhaled drug. Because they are breath-actuated, DPIs remove the need for inhalation-actuation synchrony, but there is evidence that patient errors in use of DPIs may be similar to those with MDIs. One of the biggest problems is loading and priming the DPI for use, and this may be due to the fact that every DPI model in current use is different. Medical personnel's knowledge of correct DPI use has also been shown to be lacking. The optimum inhalation profiles are different for the various DPIs, but, generally, chronic obstructive pulmonary disease patients have been shown to achieve a minimum therapeutic dose, although the inhaled amount may be suboptimal. A limitation of DPIs that have multidose powder reservoirs (eg, the Turbuhaler) is ambient humidity, which can reduce the released dose. Small-volume nebulizers are limited by bulk, treatment time, and variable performance, but are easy for patients to use. Important features identified by patients for an ideal inhaler are ease of use during an attack, dose counter, and general ease of use and learning. A breath-actuated-pMDI, such as the Autohaler, ranked at the top of inhaler preference in a study of 100 patients with airflow obstruction, compared to DPIs and MDIs. Short of a universal simple inhaler, patient and caregiver education remains the best solution to correct patient errors in use.
    MeSH term(s) Administration, Inhalation ; Aerosols/administration & dosage ; Aerosols/therapeutic use ; Clinical Competence ; Equipment Design ; Humans ; Inhalation Spacers ; Medication Errors ; Metered Dose Inhalers ; Nebulizers and Vaporizers ; Patient Education as Topic ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Self Administration
    Chemical Substances Aerosols
    Language English
    Publishing date 2006-02
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 603252-7
    ISSN 0020-1324 ; 0098-9142
    ISSN 0020-1324 ; 0098-9142
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top